{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:12:54Z","timestamp":1792134774303,"version":"4.4.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prostate-specific membrane antigen positron emission tomography (PSMA-PET) is an essential tool for patient selection before radioligand therapy (RLT). Interim-staging with PSMA-PET during RLT allows for therapy monitoring. However, its added value over post-treatment imaging is poorly elucidated. The aim of this study was to compare early treatment response assessed by post-therapeutic whole-body scans (WBS) with interim-staging by PSMA-PET after 2 cycles in order to prognosticate OS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Men with metastasized castration-resistant PC\u00a0(mCRPC) who had received at least two cycles of RLT, and interim PSMA-PET were evaluated retrospectively. PROMISE V2 framework was used to categorize PSMA expression and assess response to treatment. Response was defined as either disease control rate\u00a0(DCR) for responders or progression for non-responders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 188 men with mCRPC who underwent RLT between February 2015 and December 2021 were included. The comparison of different imaging modalities revealed a strong and significant correlation with Cramer V test: e.g. response on WBS during second cycle compared to interim PET after two cycles of RLT (c<jats:sub>\u03c6<\/jats:sub> = 0.888, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001, <jats:italic>n<\/jats:italic>\u2009=\u2009188). The median follow-up time was 14.7 months (range: 3\u201363 months; 125 deaths occurred). Median overall survival (OS) time was 14.5 months (95% CI: 11.9\u201315.9). In terms of OS analysis, early progression during therapy revealed a significantly higher likelihood of death: e.g. second cycle WBS (15 vs. 25 months, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) with a HR of 2.81 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) or at PET timepoint after 2 cycles of RLT (11 vs. 24 months, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) with a HR of 3.5 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). For early biochemical response, a PSA decline of at least 50% after two cycles of RLT indicates a significantly lower likelihood of death (26 vs. 17 months, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) with a HR of 0.5 (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Response assessment of RLT by WBS and interim PET after two cycles of RLT have high congruence and can identify patients at risk of poor outcome. This indicates that interim PET might be omitted for response assessment, but future trials corroborating these findings are warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40644-024-00773-w","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T13:28:14Z","timestamp":1726752494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Early treatment response assessment with [177Lu]PSMA whole-body-scintigraphy compared to interim PSMA-PET"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4346-2606","authenticated-orcid":false,"given":"David","family":"Ventura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Rassek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak Han","family":"Akkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linus","family":"Bredensteiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"B\u00f6gemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Schlack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sch\u00e4fers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Roll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kambiz","family":"Rahbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"773_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/CAAC.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/CAAC.21660.","journal-title":"CA Cancer J Clin"},{"key":"773_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00950-8","author":"S Sandhu","year":"2021","unstructured":"Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate Cancer. Lancet. 2021. https:\/\/doi.org\/10.1016\/S0140-6736(21)00950-8. 398;1075\u20131090.","journal-title":"Lancet"},{"key":"773_CR3","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a Randomized, Phase III Study of Androgen Deprivation Therapy with Enzalutamide or Placebo in Men with metastatic hormone-sensitive prostate Cancer. J Clin Oncol. 2019;37:2974\u201386. https:\/\/doi.org\/10.1200\/JCO.19.00799.","journal-title":"J Clin Oncol"},{"key":"773_CR4","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMRA1701695","volume":"378","author":"O Sartor","year":"2018","unstructured":"Sartor O, de Bono JS. Metastatic prostate Cancer. N Engl J Med. 2018;378:645\u201357. https:\/\/doi.org\/10.1056\/NEJMRA1701695.","journal-title":"N Engl J Med"},{"key":"773_CR5","doi-asserted-by":"publisher","unstructured":"Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A et al. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. Eur Urol. 2022;82:115\u2013141. https:\/\/doi.org\/10.1016\/J.EURURO.2022.04.002","DOI":"10.1016\/J.EURURO.2022.04.002"},{"key":"773_CR6","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMOA1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate Cancer. N Engl J Med. 2020;382:2091\u2013102. https:\/\/doi.org\/10.1056\/NEJMOA1911440.","journal-title":"N Engl J Med"},{"key":"773_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","volume":"38","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate Cancer: Multicohort, open-label phase II KEYNOTE-199 study. J Clin Oncol. 2020;38:395\u2013405. https:\/\/doi.org\/10.1200\/JCO.19.01638.","journal-title":"J Clin Oncol"},{"key":"773_CR8","doi-asserted-by":"publisher","first-page":"574","DOI":"10.2967\/JNUMED.122.264456","volume":"64","author":"K Rahbar","year":"2023","unstructured":"Rahbar K, Essler M, Pabst KM, Eiber M, la Foug\u00e8re C, Prasad V, et al. Safety and survival outcomes of 177Lu-Prostate-specific membrane Antigen Therapy in patients with metastatic castration-resistant prostate Cancer with prior 223Ra treatment: the RALU Study. J Nucl Med. 2023;64:574. https:\/\/doi.org\/10.2967\/JNUMED.122.264456.","journal-title":"J Nucl Med"},{"key":"773_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMOA1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha Emitter Radium-223 and survival in metastatic prostate Cancer. N Engl J Med. 2013;369:213\u201323. https:\/\/doi.org\/10.1056\/NEJMOA1213755.","journal-title":"N Engl J Med"},{"key":"773_CR10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMOA2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385:1091. https:\/\/doi.org\/10.1056\/NEJMOA2107322.","journal-title":"N Engl J Med"},{"key":"773_CR11","doi-asserted-by":"publisher","unstructured":"Hoffman A, Amiel GE. The impact of PSMA PET\/CT on modern prostate Cancer Management and decision making-the Urological Perspective. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/CANCERS15133402.","DOI":"10.3390\/CANCERS15133402"},{"key":"773_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2967\/JNUMED.120.246363","volume":"62","author":"K Sprute","year":"2021","unstructured":"Sprute K, Kramer V, Koerber SA, Meneses M, Fernandez R, Soza-Ried C, et al. Diagnostic accuracy of 18F-PSMA-1007 PET\/CT Imaging for Lymph Node Staging of Prostate Carcinoma in primary and biochemical recurrence. J Nucl Med. 2021;62:208\u201313. https:\/\/doi.org\/10.2967\/JNUMED.120.246363.","journal-title":"J Nucl Med"},{"key":"773_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/J.EUF.2021.01.016","volume":"7","author":"V Murthy","year":"2021","unstructured":"Murthy V, Sonni I, Jariwala N, Juarez R, Reiter RE, Raman SS, Hope TA. The role of PSMA PET\/CT and PET\/MRI in the initial staging of prostate Cancer. Eur Urol Focus. 2021;7:258\u201366. https:\/\/doi.org\/10.1016\/J.EUF.2021.01.016.","journal-title":"Eur Urol Focus"},{"key":"773_CR14","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/J.CPET.2021.03.004","volume":"16","author":"R Seifert","year":"2021","unstructured":"Seifert R, Alberts IL, Afshar-Oromieh A, Rahbar K. Prostate Cancer Theranostics: PSMA targeted therapy. PET Clin. 2021;16:391\u20136. https:\/\/doi.org\/10.1016\/J.CPET.2021.03.004.","journal-title":"PET Clin"},{"key":"773_CR15","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/S00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, et al. Joint EANM\/SNMMI Procedure Guideline for the use of 177Lu-Labeled PSMA-Targeted Radioligand-Therapy (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50:2830\u201345. https:\/\/doi.org\/10.1007\/S00259-023-06255-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"773_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/J.EURURO.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second Version of the prostate Cancer molecular imaging standardized evaluation Framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83:405\u201312. https:\/\/doi.org\/10.1016\/J.EURURO.2023.02.002.","journal-title":"Eur Urol"},{"key":"773_CR17","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial Design and objectives for castration-resistant prostate Cancer: updated recommendations from the prostate Cancer clinical trials Working Group 3. J Clin Oncol. 2016;34:1402\u201318. https:\/\/doi.org\/10.1200\/JCO.2015.64.2702.","journal-title":"J Clin Oncol"},{"key":"773_CR18","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2967\/JNUMED.122.264398","volume":"64","author":"S Pathmanandavel","year":"2023","unstructured":"Pathmanandavel S, Crumbaker M, Ho B, Yam AO, Wilson P, Niman R, et al. Evaluation of 177Lu-PSMA-617 SPECT\/CT Quantitation as a response Biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN). J Nucl Med. 2023;64:221\u20136. https:\/\/doi.org\/10.2967\/JNUMED.122.264398.","journal-title":"J Nucl Med"},{"key":"773_CR19","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2967\/JNUMED.122.264677","volume":"64","author":"N John","year":"2023","unstructured":"John N, Pathmanandavel S, Crumbaker M, Counter W, Ho B, Yam AO, et al. 177Lu-PSMA SPECT quantitation at 6 weeks (dose 2) predicts short progression-free survival for patients undergoing 177Lu-PSMA-I&T therapy. J Nucl Med. 2023;64:410\u20135. https:\/\/doi.org\/10.2967\/JNUMED.122.264677.","journal-title":"J Nucl Med"},{"key":"773_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/S00259-023-06536-2","author":"MC Neubauer","year":"2023","unstructured":"Neubauer MC, Nicolas GP, Bauman A, Fani M, Nitzsche E, Afshar-Oromieh A, et al. Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT\/CT Predicts Overall Survival of MCRPC patients: Subgroup Analysis of a swiss-wide prospective Registry Study. Eur J Nucl Med Mol Imaging. 2023. https:\/\/doi.org\/10.1007\/S00259-023-06536-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"773_CR21","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1055\/A-2127-7880","volume":"62","author":"P Rassek","year":"2023","unstructured":"Rassek P, Sch\u00e4fers M, Rahbar K, Backhaus P. [18F]-PSMA-1007-PET for evaluation of kidney function. Nuklearmedizin. 2023;62:244\u201351. https:\/\/doi.org\/10.1055\/A-2127-7880.","journal-title":"Nuklearmedizin"},{"issue":"4","key":"773_CR22","doi-asserted-by":"publisher","first-page":"e222010","DOI":"10.1148\/radiol.222010","volume":"307","author":"R Seifert","year":"2023","unstructured":"Seifert R, Rasul S, Seitzer K, Eveslage M, Nikoukar LR, Kessel K, et al. A prognostic risk score for prostate Cancer based on PSMA PET\u2013Derived organ-specific Tumor volumes. Radiology. 2023;307(4):e222010. https:\/\/doi.org\/10.1148\/radiol.222010.","journal-title":"Radiology"},{"key":"773_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/BJU.14876","volume":"124","author":"MS Hofman","year":"2019","unstructured":"Hofman MS, Emmett L, Violet JY, Zhang A, Lawrence NJ, Stockler M, et al. TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs Cabazitaxel in Progressive Metastatic Castration-resistant prostate Cancer (Clinical Trial Protocol ANZUP 1603). BJU Int. 2019;124:5\u201313. https:\/\/doi.org\/10.1111\/BJU.14876.","journal-title":"BJU Int"},{"key":"773_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/JNUMED.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German Multicenter Study investigating 177Lu-PSMA-617 Radioligand therapy in advanced prostate Cancer patients. J Nucl Med. 2017;58:85\u201390. https:\/\/doi.org\/10.2967\/JNUMED.116.183194.","journal-title":"J Nucl Med"},{"key":"773_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/S00259-023-06476-X","author":"C Burgard","year":"2023","unstructured":"Burgard C, Hein C, Blickle A, Bartholom\u00e4 M, Maus S, Petto S, et al. Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 Radioligand Therapy predicts overall survival in patients with MCRPC: monocentric evaluation of a prospective Registry. Eur J Nucl Med Mol Imaging. 2023. https:\/\/doi.org\/10.1007\/S00259-023-06476-X.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"773_CR26","doi-asserted-by":"publisher","first-page":"8143","DOI":"10.7150\/THNO.60222","volume":"11","author":"R Seifert","year":"2021","unstructured":"Seifert R, Kessel K, Schlack K, Weckesser M, Kersting D, Seitzer KE, et al. Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA Therapy. Theranostics. 2021;11:8143\u201351. https:\/\/doi.org\/10.7150\/THNO.60222.","journal-title":"Theranostics"},{"issue":"24","key":"773_CR27","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.2217\/fon-2018-0087","volume":"14","author":"D Heinrich","year":"2018","unstructured":"Heinrich D, Bruland O, Guise TA, Suzuki H, Sartor O. Alkaline phosphatase in metastatic castration-resistant prostate Cancer: reassessment of an older biomarker. Future Oncol. 2018;14(24):2543\u201356. https:\/\/doi.org\/10.2217\/fon-2018-0087.","journal-title":"Future Oncol"},{"key":"773_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5301\/uro.5000206","volume":"84","author":"P Scalzi","year":"2017","unstructured":"Scalzi P, Baiocco C, Genovese S, Trevisan A, Sirotova Z, Poti C. Evaluation of bone metastases by 18F-Choline PET\/CT in a patient with castration-resistant prostate Cancer treated with Radium-223. Urologia. 2017;84:61\u20134. https:\/\/doi.org\/10.5301\/uro.5000206.","journal-title":"Urologia"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-024-00773-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-024-00773-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-024-00773-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T13:35:14Z","timestamp":1726752914000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-024-00773-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["773"],"URL":"https:\/\/doi.org\/10.1186\/s40644-024-00773-w","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"19 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the University of M\u00fcnster (No. 2019\u2013711-f-S).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KR reports honoraria from Advanced Accelerator Applications (AAA\/Novartis), Bayer, Jahnsen Cielag, Amgen, Astrazeneca and Pharmtrace and a consultancy\/advisory role with ABX GmbH, ABX-CRO, Bayer, and AAA\/Novartis and UroTrials.MB receives honoraria from and has a consultancy\/advisory role with Advanced Accelerator Applications (AAA\/Novartis), Bayer, Janssen, Sanofi, Merck, MSD, BMS, Roche, Astellas, Exelixis, Pahrmtrace, Amgen, AstraZeneca, Eisai, Gilead, and EUSApharma.RS has received research support from Boehringer Ingelheim Funds and Else Kr\u00f6ner-Fresenius-Stiftung.All other authors have declared that no competing interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"126"}}